ACT Brief: RBQM Financial Value Quantification, Trial Budget Cost Visibility Gap, and GSK mRNA Flu Vaccine Phase III

In today's ACT Brief, we examine how eNPV modeling and real-world data finally put numbers on RBQM value, why static budgeting masks true site costs, and GSK advancing an mRNA flu vaccine candidate to late-stage testing.